英国首富、戴森（Dyson）公司创始人詹姆斯·戴森（James Dyson）近日对其家族财富管理架构进行了 重大调整。根据对公司注册文件的分析，戴森家族的投资公司韦伯恩（Weybourne Group）2025年从其 英国主要实体向新加坡控股公司转移了至少6.24亿英镑的资金，使得英国实体的账面资本仅剩1英镑。 （新浪财经） ...

作者丨彭鑫 截至2025年10月8日24时的小客车指标申请，经审核，家庭普通小客车指标申请共计624185个有效编 码，个人普通小客车指标申请共计2624575个有效编码，单位普通小客车指标申请共计52455家。 审核（含复核）结果已于2025年12月25日公布，申请人可登录北京市小客车指标调控管理信息系统或到 各区对外办公窗口（办公地点和时间可登录系统，首页-办事专栏查看《小客车指标申请各区对外办公 窗口》）查询审核结果。 编辑丨安安 12月25日，北京市机动车调控管理办公室发布关于2025年第2期普通小客车指标申请审核结果和配置工 作有关事项的通告。 按照《<北京市小客车数量调控暂行规定>实施细则》（2025年修订）相关规定，现就2025年第2期普通 小客车指标申请配置工作安排的具体事项通告如下： 12月26日10:00，按照"公开、公平、公正和促进公共资源均衡配置"的原则进行配置。配置现场将在公 证人员的公证下，选取申请人代表、操作设备、生成随机种子数、产生配置结果。配置现场对媒体开 放，首都之窗负责现场网络直播。 一、申请审核情况 由于指标配置当日网站访问量较大，建议申请人错峰查询。 四、指标使用提示 ...

近日，国务院国资委党委书记、主任张玉卓表示，要接续发力新能源、新能源汽车、新材料、航空航 天、低空经济、量子科技、6G等重点领域，加大启航企业遴选培育力度。接续推动技术改造和大规模 设备更新，深入推进重点行业节能降碳改造。 编辑丨安安 作者丨彭鑫 ...

Core Viewpoint - Gilead's drug Seladelpar for primary biliary cholangitis (PBC) has been officially approved in the Boao Lecheng International Medical Tourism Pilot Zone, providing a new treatment option for PBC patients in China [1] Group 1: Drug Approval and Indications - Seladelpar is a potent selective peroxisome proliferator-activated receptor delta (PPARδ) agonist approved for the treatment of PBC [1] - The drug is indicated for adult patients with PBC who have an inadequate response to monotherapy with ursodeoxycholic acid (UDCA) or as a monotherapy for those who cannot tolerate UDCA [1] Group 2: Impact on Rare Disease Treatment - The approval of Seladelpar reflects China's ongoing efforts to enhance the accessibility of innovative drugs for rare diseases and to meet unmet clinical needs [1] - PBC has been included in China's "Second Batch of Rare Disease Catalog," highlighting the importance of addressing rare diseases in the healthcare system [1]

Core Insights - Maikang Bio announced the completion of a multi-hundred million yuan D+ round financing on December 25, with investments from Chengdu Science and Technology Investment, Shenzhen Capital Group, Guosheng Capital, and Linchuang Lanwan [1] Group 1: Financing Details - The funds raised will primarily support the market launch and commercialization of the recombinant shingles vaccine, the Phase III clinical research of the recombinant respiratory syncytial virus vaccine, and the preclinical development of multiple innovative vaccine pipelines and international collaborations [1] Group 2: Company Background - Established in 2016, Maikang Bio is a global biopharmaceutical company focused on the research, development, production, and commercialization of innovative vaccines and novel adjuvants [1] - The company was founded by Dr. Chen Dexiang, a returnee PhD, and has been recognized as a national high-tech enterprise and a specialized and innovative enterprise in Sichuan Province, consistently listed in the GEI China (potential) unicorn enterprises list [1]

这三款产品分别为瑞可妥、瑞百莱和美比瑞，均适用于精神分裂症的治疗。恩华和信将负责以上产品在 中国大陆的独家经销与商业化，公司则继续持有该三款产品的资产权、注册证及全部知识产权等权利， 并负责产品的生产和供货。协议期限为10年，恩华将一次性支付公司不可退还的2000万美元授权费。 近日，绿叶制药发布公告，公司与恩华药业（002262）的附属公司江苏恩华和信医药营销有限公司签署 合作协议，授予恩华和信三款抗精神病药长效针剂产品在中国大陆地区的独家商业化权利。 ...

Core Viewpoint - The company has noted the approval of a generic version of its marketed product Budesonide Enteric-Coated Capsules (Nafacon) [1] Group 1 - The original product Nafacon is protected by patent ZL200980127272.5 in China, which is currently valid until May 7, 2029 [1] - The company reserves the right to take legal action against any infringement of the patent rights and commitments [1]

Core Viewpoint - The company, YaoYigou (300937), has successfully resolved a contractual dispute, receiving a core execution payment of 44 million yuan after a final court ruling in its favor [1] Group 1: Legal Dispute Resolution - The dispute originated in November 2022 when plaintiffs Yang Ya and Cao Jijun sued YaoYigou regarding a cooperation agreement in the Huangpu District People's Court of Guangzhou [1] - In August 2024, the first-instance court ruled to terminate the relevant agreement and ordered the defendants to jointly repay the loan of 44 million yuan to YaoYigou [1] - Both parties appealed the ruling, but in October 2025, the Guangzhou Intermediate People's Court upheld the original judgment, with the opposing party bearing most of the second-instance case acceptance fees [1] Group 2: Financial Impact - As of the announcement date, YaoYigou has received the full 44 million yuan execution payment, with an estimated late payment interest of approximately 357,400 yuan currently under court verification [1] - The company has reported 54 additional undisclosed minor lawsuits and arbitration cases in the past year, with a total amount in dispute of 21.21 million yuan, primarily related to contract disputes [1] - The received 44 million yuan will be accounted for according to accounting standards, with the final impact on the company's current or future profits to be determined by the annual audit results [1]

Core Viewpoint - Aier Eye Hospital announced plans to acquire partial equity in 39 institutions, including Bozhou Aier and Lianyungang Aier, for a total amount of 963 million yuan, funded by the company's own resources [1] Group 1: Acquisition Details - The board meeting is scheduled for December 24, 2025, to review the acquisition proposal [1] - The total transaction amount is 963 million yuan [1] Group 2: Strategic Intent - The company aims to enhance its market share and competitiveness through external mergers and acquisitions [1] - The acquisition is part of the company's strategy to accelerate national network construction and improve its outlet layout [1] - This move is intended to solidify the company's leading position in the ophthalmology medical market [1]

12月25日，据北京规自委消息，北京建工+城乡开发联合体以底价24.72亿元竞得北京市丰台区花乡中部 组团城中村改造项目BXFT00-2405-0001地块，楼面价约4.2万/㎡。地块用地面积约2.35万㎡，建筑规模 约5.89万㎡，容积率为2.5。该地块位于丰台区玉泉营街道南三环到四环间，距离地铁房山线花乡东桥站 约600米、距离地铁10号线与房山线换乘首经贸站约1公里，周边还有天坛生活广场、花乡奥莱村、纪家 庙公园、首都医科大学附属北京天坛医院等生活配套。这是北京年内最后一次土拍，共收金1427.4亿 元。 北京年内最后一次土拍，共收金1427.4亿元。 ...